IDEXX Laboratories Nears Record Highs on Strong Companion Animal Diagnostics Growth

Key Facts

1IDEXX Laboratories stock is trading near record levels driven by revenue growth in its companion animal diagnostics segment.

2The company reported approximately $4.0 billion in total revenue for fiscal 2024, with the diagnostics segment growing by 10%.

Reflecting strong momentum in the specialized healthcare sector, IDEXX Laboratories stock is trading near record levels driven by revenue growth in its companion animal diagnostics segment. According to reports, the company achieved total revenue of approximately $4.0 billion for fiscal 2024, with its core diagnostics business growing by 10%. This performance is underpinned by a recurring revenue model from diagnostic analyzers and consumables.

The upward trend highlights solid operating margins and fundamental strength within the company's primary business lines. Per market data, peer instrument DXCM closed at $74.75 (close July 21, 2026), illustrating the broader trading environment for medical diagnostic and device equities during this period.

IDEXX stock (0J8P.L) stood at $553.47 at close July 21, 2026, after reaching a session high of $562.25. As there are no immediate sector-specific catalysts in the upcoming economic calendar, investors will focus on whether the stock can sustain its trajectory toward new record highs based on its recurring revenue strength.